These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
573 related articles for article (PubMed ID: 16104989)
1. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989 [TBL] [Abstract][Full Text] [Related]
2. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408 [TBL] [Abstract][Full Text] [Related]
3. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
4. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kielberger L; Bouda M; Jindra P; Reischig T Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Ahsan N; Holman MJ; Yang HC Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699 [TBL] [Abstract][Full Text] [Related]
7. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994 [TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964 [TBL] [Abstract][Full Text] [Related]
9. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113 [TBL] [Abstract][Full Text] [Related]
10. The economic value of valacyclovir prophylaxis in transplantation. Squifflet JP; Legendre C J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196 [TBL] [Abstract][Full Text] [Related]
11. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653 [TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir. Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766 [No Abstract] [Full Text] [Related]
13. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302 [TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
15. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis. Leong RW; Smith DW; Garas G; Beaman JM; Mitchell AW; Heath DI; House AK; Jeffrey GP Intern Med J; 2004 Jul; 34(7):410-5. PubMed ID: 15271175 [TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC; Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359 [TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
18. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133 [TBL] [Abstract][Full Text] [Related]
19. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
20. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Kacer M; Kielberger L; Bouda M; Reischig T Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]